1. Home
  2. MXL vs BEAM Comparison

MXL vs BEAM Comparison

Compare MXL & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MXL
  • BEAM
  • Stock Information
  • Founded
  • MXL 2003
  • BEAM 2017
  • Country
  • MXL United States
  • BEAM United States
  • Employees
  • MXL N/A
  • BEAM N/A
  • Industry
  • MXL Semiconductors
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MXL Technology
  • BEAM Health Care
  • Exchange
  • MXL Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • MXL 1.4B
  • BEAM 1.7B
  • IPO Year
  • MXL 2010
  • BEAM 2020
  • Fundamental
  • Price
  • MXL $15.96
  • BEAM $23.85
  • Analyst Decision
  • MXL Buy
  • BEAM Strong Buy
  • Analyst Count
  • MXL 8
  • BEAM 10
  • Target Price
  • MXL $20.93
  • BEAM $49.78
  • AVG Volume (30 Days)
  • MXL 1.1M
  • BEAM 3.0M
  • Earning Date
  • MXL 10-22-2025
  • BEAM 11-04-2025
  • Dividend Yield
  • MXL N/A
  • BEAM N/A
  • EPS Growth
  • MXL N/A
  • BEAM N/A
  • EPS
  • MXL N/A
  • BEAM N/A
  • Revenue
  • MXL $378,015,000.00
  • BEAM $60,272,000.00
  • Revenue This Year
  • MXL $28.85
  • BEAM N/A
  • Revenue Next Year
  • MXL $17.69
  • BEAM $18.20
  • P/E Ratio
  • MXL N/A
  • BEAM N/A
  • Revenue Growth
  • MXL N/A
  • BEAM N/A
  • 52 Week Low
  • MXL $8.35
  • BEAM $13.53
  • 52 Week High
  • MXL $25.73
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • MXL 49.89
  • BEAM 63.60
  • Support Level
  • MXL $15.41
  • BEAM $22.50
  • Resistance Level
  • MXL $17.19
  • BEAM $25.09
  • Average True Range (ATR)
  • MXL 0.70
  • BEAM 1.44
  • MACD
  • MXL -0.05
  • BEAM 0.09
  • Stochastic Oscillator
  • MXL 34.83
  • BEAM 71.48

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: